Substance

ID:348260

Names and Identifiers
IUPAC name
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide
Synonyms
CosudexCasodexN-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamideBicalutamide (CDX)
IUPAC Traditional name
bicalutamide
Registration numbers
CAS Number
MDL Number
Properties
Safety Information
German water hazard class
3
GHS Hazard statements
H315-H319-H335
Storage Condition
protect from light
desiccated
GHS Signal Word
Warning
MSDS Link
GHS Precautionary statements
P261-P305+P351+P338
Safety Statements
26
GHS Pictograms
GHS07
Acute toxicity (oral, dermal, inhalation), category 4
Skin irritation, category 2
Eye irritation, category 2
Skin sensitisation, category 1
Specific Target Organ Toxicity – Single exposure, category 3
Risk Statements
36/37/38
RTECS
TX1413500
European Hazard Symbols
Irritant Irritant (Xi)
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Physical Property
Apperance
powder
Solubility
H2O: insoluble
DMSO: >5 mg/mL
Product Information
Empirical Formula (Hill Notation)
C18H14F4N2O4S
Purity
≥98% (HPLC)
Molecule Details
Biochem/physiol Actions
Bicalutamide (CDX) is a non-steriodal Androgen Receptor (AR) antagonist and a pure antiandrogen. It acts via balancing histone acetylation/deacetylation and recruitment of coregulators. Bicalutamide (CDX) abolishes androgen-mediated expression. For example, MMP13 upregulation in prostate cancer, PLZF (promyelocytic leukemia zinc finger protein), and GADD45γ (growth arrest and DNA damage inducible, gamma). Bicalutamide (CDX) is inhibited by non-genomic, transcription-independent stimulation of PI3K/AKT phosphorylation by androgens.
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data